Table 2.
Clinical features of EOC patients involved in the study.
| Sample | Histotype | Stage | Grade | Chemotherapy | CD117 enrichment * |
|---|---|---|---|---|---|
| 49 III | Serous-papillary | 3C | 3 | Yes | 7.08 |
| 49 V | Serous-papillary | 3C | 3 | Yes | 2.41 |
| 84 IV | Serous-papillary | 3C | 3 | Yes | 4.02 |
| 98 | Serous | 3B | 1 | No | 21.53 |
| 101 | Serous | 3C | 3 | Yes | 4.37 |
| 106 | Bilateral serous-papillary | 4 | 3 | No | 5.99 |
* CD117 mRNA expression (fold change) between CD44+CD117+ and CD44+CD117− FACS-sorted populations. This parameter is used to check by an orthogonal technique CSC enrichment after sorting, EOC, Epithelial ovarian cancer.